At Zynerba Pharmaceuticals, we are dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for rare and near-rare neuropsychiatric conditions in patients with high unmet medical needs.

Our mission is to improve the lives of patients battling severe neuropsychiatric conditions including Fragile X syndrome, refractory focal epilepsy, and developmental and epileptic encephalopathies (DEE).

Our development pipeline includes clinical programs in a number of neuropsychiatric conditions with a patent-protected pharmaceutically-produced transdermal cannabinoid product, which we believe may provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.


ZYN002 – CBD Gel

ZYN002 is the first and only pharmaceutically-produced CBD, a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is being developed for patients suffering from Fragile X syndrome (FXS) and certain refractory epilepsies including DEEs. The U.S. Food and Drug Administration has granted Orphan Drug designation to Zynerba for the use of CBD as treatment of patients with FXS.